Hepatology：EBR/GZR联合SOF治疗HCV基因3型代偿性肝硬化患者初治和经治患者疗效良好

2018-03-17 MedSci MedSci原创

HCV GT3感染和肝硬化患者表现出较高的疗效。超过12周的治疗是不需要的，而且不论基线RASs如何，直接抗病毒疗效都维持不变。本研究的表明，EBR/GZR联合SOF治疗HCV基因3型代偿性肝硬化患者初治和经治患者疗效良好

研究背景：直接抗病毒治疗药物治疗HCV患者，疗效显著、安全性较好。本研究的目的是评估elbasvir/grazoprevir (EBR/GZR)+ 索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV 基因3型代偿性肝硬化患者的效果。

研究方法：本研究为2期、随机、开放标签研究。初治患者接受EBR/GZR + SOF + RBV治疗8周或接受EBR/GZR + SOF治疗12周；聚乙二醇干扰素/RBV经治的患者，接受EBR/GZR + SOF +/- RBV治疗12周或EBR/GZR + SOF治疗16周。研究主要终点为治疗结束后12周，血清HCV RNA <15 IU/mL。

研究结果：接受EBR/GZR + SOF + RBV治疗8周，未治患者SVR12为91% (21/23)；接受EBR/GZR + SOF治疗12周，未治患者SVR12为96% (23/24)。接受EBR/GZR + SOF - RBV治疗12周、EBR/GZR + SOF +RBV治疗12周和EBR/GZR + SOF治疗16周的患者，SVR12分别为94% (17/18)、100% (17/17)、94% (17/18)。5例参与者未能获得SVR，2例患者发生HCV复发（都出现在8周治疗组），1例因呕吐/蜂窝织炎而中断（16周治疗组），2例停止治疗(同意撤回/失去后续行动)。SVR12不受耐药相关替代(RASs)的影响。胰岛素抵抗没有持续的变化，5名参与者报告严重的不良反应(肺炎、胸痛、阿片过量、细胞炎、肌酐减少)。

研究结论：HCV GT3感染和肝硬化患者表现出较高的疗效。超过12周的治疗是不需要的，而且不论基线RASs如何，直接抗病毒疗效都维持不变。本研究的表明，EBR/GZR联合SOF治疗HCV基因3型代偿性肝硬化患者初治和经治患者疗效良好。

原始出处

Foster GR， Agarwal K， Cramp ME， et al. Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis： A Randomized Trial. Hepatology， 2018， Feb 23. doi： 10.1002/hep.29852.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-09-09 ms5106640509429053

#代偿性肝硬化#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-05-30 pyaili

#经治患者#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-03-19 ymljack

#HCV#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-03-19 gwc384

#EPA#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-03-17 有备才能无患

直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果.

66 0
[GetPortalCommentsPageByObjectIdResponse(id=2077556, encodeId=c29f20e7556a2, content=<a href='/topic/show?id=94c7253e768' target=_blank style='color:#2F92EE;'>#代偿性肝硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25377, encryptionId=94c7253e768, topicName=代偿性肝硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Sep 09 23:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805487, encodeId=ecfa180548ed9, content=<a href='/topic/show?id=63c2e8331df' target=_blank style='color:#2F92EE;'>#经治患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78331, encryptionId=63c2e8331df, topicName=经治患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed May 30 19:50:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257725, encodeId=f400125e72539, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427043, encodeId=6356142e0431b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Mar 19 11:50:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297166, encodeId=80cf29e166d0, content=直接抗病毒治疗药物治疗HCV患者.疗效显著.安全性较好.本研究的目的是评估elbasvir/grazoprevir(EBR/GZR)+索非布韦(SOF)联合利巴韦林(RBV)或不联合利巴韦林(RBV)治疗HCV基因3型代偿性肝硬化患者的效果., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Mar 17 21:36:18 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297164, encodeId=22b929e164dc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Sat Mar 17 20:56:18 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
2018-03-17 九九消寒

优质资源.共同学习

72 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肝病

Hepatology：EBR/GZR联合SOF治疗HCV基因3型代偿性肝硬化患者初治和经治患者疗效良好

相关资讯

科室

工具

服务

肝病

Hepatology：EBR/GZR联合SOF治疗HCV基因3型代偿性肝硬化患者初治和经治患者疗效良好

相关资讯

J Viral Hepat：Simeprevir, daclatasvir和sofosbuvir治疗HCV 基因1型感染患者的疗效和安全性

South Med J：先天性心脏病患者中HCV的流行率和直接抗病毒治疗的效果

科室

工具

服务